NCT02113644

Brief Summary

The aim of Prevent CardioKids is to evaluate to what extend disturbed vascular function markers are already present in children of different weight categories and whether these are age dependent. Also differences - and relationships - between vascular function measurements and plasma biomarkers between lean and overweight/obese children will be compared.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
240

participants targeted

Target at P75+ for all trials

Timeline
35mo left

Started Apr 2014

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress81%
Apr 2014Apr 2029

First Submitted

Initial submission to the registry

October 23, 2013

Completed
5 months until next milestone

Study Start

First participant enrolled

April 1, 2014

Completed
13 days until next milestone

First Posted

Study publicly available on registry

April 14, 2014

Completed
15 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 1, 2029

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

April 1, 2029

Last Updated

April 29, 2020

Status Verified

April 1, 2020

Enrollment Period

15 years

First QC Date

October 23, 2013

Last Update Submit

April 28, 2020

Conditions

Outcome Measures

Primary Outcomes (1)

  • Vascular function measured by peripheral arterial tonometry (EndoPAT)

    The primary endpoint is the difference in micro- and macrovascular characteristics, as measured by EndoPAT in lean/overweight/obese children in different age groups.

    1 year

Secondary Outcomes (3)

  • Differences in characteristics of the microcirculation as measured via fundus photography

    1 year

  • Differences in characteristics of microcirculation measured via lipoprotein profiles

    1 year

  • Differences in characteristics of the microcirculation as measured via pro-inflammatory profiles

    1 year

Study Arms (2)

Overweight or obese children

Overweight or obese children according to the International Obesity Task Force (IOTF) criteria following the lifestyle intervention in the Centre for Overweight Adolescent and Children's Healthcare

Other: Lifestyle intervention

Lean children

Lean children according to the International Obesity Task Force (IOTF) criteria admitted at de pediatric ward for a planned surgery, for example the correction of floppy ears

Interventions

Overweight or obese children

Eligibility Criteria

Age6 Years - 18 Years
Sexall
Healthy VolunteersYes
Age GroupsChild (0-17), Adult (18-64)
Sampling MethodNon-Probability Sample
Study Population

Overweight or obese children according to the International Obesity Task Force (IOTF) criteria between 6-18 years old. Overweight and obese children will be recruited in the COACH program. For the control group healthy, normal weight children between 6-18 years old.

You may qualify if:

  • Participation in the COACH program
  • Overweight or obesity according to IOTF criteria
  • In order to be eligible to participate in the control group, a subject must meet all of the following criteria:
  • Aged between 6 and 18 years
  • Normal weight according to the IOTF criteria
  • Undergo surgery for elective reasons

You may not qualify if:

  • Retarded children
  • Children suffering from:
  • Inflammatory diseases: auto-immune diseases, inflammatory bowel diseases, hepatitis, dermatitis, nephritis, pancreatitis, gastro-enteritis, vasculitis, salpingitis, arthritis, osteomyelitis, myositis, ear-nose-throat infections
  • Allergic diseases: asthma, eczema, hay fever, food allergies
  • Oncologic diseases
  • Cystic fibrosis
  • Type 1 diabetes mellitus
  • Congenital metabolic diseases
  • Malnourished children

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Maastricht University Medical Center

Maastricht, Limburg, 6202AZ, Netherlands

RECRUITING

Related Links

MeSH Terms

Conditions

Cardiovascular Diseases

Study Officials

  • Anita Vreugdenhil, dr.

    Maastricht University Medical Center

    PRINCIPAL INVESTIGATOR

Central Study Contacts

A. Vreugdenhil, Dr.

CONTACT

K. Karnebeek, Drs.

CONTACT

Study Design

Study Type
observational
Observational Model
OTHER
Time Perspective
CROSS SECTIONAL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

October 23, 2013

First Posted

April 14, 2014

Study Start

April 1, 2014

Primary Completion (Estimated)

April 1, 2029

Study Completion (Estimated)

April 1, 2029

Last Updated

April 29, 2020

Record last verified: 2020-04

Locations